A sympatholytic (or sympathoplegic) drug is a medication that opposes the downstream effects of postganglionic nerve firing in effector organs innervated by the sympathetic nervous system (SNS). They are indicated for various functions; for example, they may be used as antihypertensives. They are also used to treat anxiety, such as generalized anxiety disorder, panic disorder and PTSD.
Mechanisms of action
Antiadrenergic agents inhibit the signals of epinephrine and norepinephrine. They are primarily postsynaptic adrenergic receptor antagonists (alpha and beta adrenergic receptor antagonists, or "blockers"), inhibiting the downstream cellular signaling pathways of adrenergic receptors. However, there are exceptions: clonidine is an adrenergic agonist at the α2 receptor; since this receptor is located presynaptically, agonism at this receptor inhibits the presynaptic release of adrenaline and noradrenaline, preventing postsynaptic adrenergic receptor activation and downstream signaling.
For neurotransmitters to be released, they first must be stored in synaptic vesicles. Reserpine works by inhibiting VMAT, preventing the storage of neurotransmitters into synaptic vesicles. If VMAT is inhibited, neurotransmitters won't be released into the synaptic cleft, thereby inhibiting their downstream effect.
Other drugs are preferentially toxic to sympathetic neurons. One method of obtaining such specificity is to exploit drugs that are substrates for a transporter preferentially expressed on sympathetic terminals, such as the norepinephrine transporter. Such transports allows the drugs to accumulate within sympathetic neurones, where they can act to inhibit sympathetic function. Such drugs include bretylium, guanethidine and 6-hydroxydopamine.
Many antiadrenergic agents used as antihypertensives include:
- Centrally acting
- Peripherally acting
- Guanethidine (Magnesium-ATPase inhibitor)
- Indoramin (α1 antagonist)
- Doxazosin (alpha blocker)
- Beta blockers
- Non-selective agents
- β1-selective agents
- β2-selective agents
There is clear evidence from many controlled trials in the past 25 years that beta blockers are effective in anxiety disorders, though the mechanism of action is not known.
Some people have used beta blockers for performance type social anxiety, or "stage fright." In particular, musicians, public speakers, actors, and professional dancers, have been known to use beta blockers to avoid stage fright and tremor during public performance and especially auditions. The physiological symptoms of the fight/flight response associated with performance anxiety and panic (pounding heart, cold/clammy hands, increased respiration, sweating, etc.) are significantly reduced, thus enabling anxious individuals to concentrate on the task at hand. Stutterers also use beta blockers to avoid fight/flight responses, hence reducing the tendency to stutter.
Since they promote a lower heart rate and reduce tremor, beta blockers have been used by some Olympic marksmen to enhance performance, though beta blockers are banned by the International Olympic Committee (IOC). Although they have no recognizable benefit to most sports, it is acknowledged that they are beneficial to sports such as archery and shooting. A recent, high-profile transgression took place in the 2008 Summer Olympics, where 50 meter pistol silver medalist and 10 meter air pistol bronze medalist Kim Jong-su tested positive for propranolol and was stripped of his medal.
Posttraumatic stress disorder (PTSD) is theorized to be the result of neurological patterns caused by adrenaline and fear in the brain. By administering beta blockers which can cross the blood brain barrier immediately following a traumatic event, as well as over the next couple weeks, the formation of PTSD has been reduced in clinical studies.
Alpha2 adrenergic agonist
Alpha2 adrenergic agonist can also be used to treat anxiety and panic, such as Generalized Anxiety Disorder, Panic Disorder or PTSD. Alpha2-adrenergic receptor agonists, such as clonidine and guanfacine, act at noradrenergic autoreceptors to inhibit the firing of cells in the locus ceruleus, effectively reducing the release of brain norepinephrine. Clonidine has shown promise among patients with Anxiety, Panic and PTSD in clinical trials and was used to treat severely and chronically abused and neglected preschool children. It improved disturbed behavior by reducing aggression, impulsivity, emotional outbursts, and oppositionality. Insomnia and nightmares were also reported to be reduced.
Kinzie and Leung prescribed the combination of clonidine and imipramine to severely traumatized Cambodian refugees with Anxiety, Panic and PTSD. Global symptoms of PTSD were reduced among sixty-six percent and nightmares among seventy-seven percent. Guanfacine produces less sedation than clonidine and thus may be better tolerated. Guanfacine reduced the trauma-related nightmares.
Prazosin is an α1-blocker that acts as an inverse agonist at alpha-1 adrenergic receptors. Raskind and colleagues studied the efficacy of prazosin for PTSD among Vietnam combat veterans in a 20-week double-blind crossover protocol with a two-week drug washout to allow for return to baseline. The CAPS and the Clinical Global Impressions-Change scale (CGI-C) were the primary outcome measures. Patients who were taking prazosin had a robust improvement in overall sleep quality (effect size, 1.6) and recurrent distressing dreams (effect size, 1.9). In each of the PTSD symptom clusters the effect size was medium to large: 0.7 for reexperiencing or intrusion, and 0.6 for avoidance and numbing, and .9 for hyperarousal. The reduction in CGI-C scores (overall PTSD severity and function at endpoint) also reflected a large effect size (1.4). Prazosin appears to have promise as an effective treatment for PTSD-related sleep disturbance, including trauma-related nightmares, as well as overall Anxiety and PTSD symptoms.
- "Dorlands Medical Dictionary:sympatholytic".
- Brock, JA; Cunnane, TC (November 1988). "Studies on the mode of action of bretylium and guanethidine in post-ganglionic sympathetic nerve fibres". Naunyn-Schmiedeberg's archives of pharmacology. 338 (5): 504–9. doi:10.1007/bf00179321. PMID 3244392.
- Tyrer, Peter (January 1992). "Anxiolytics not acting at the benzodiazepine receptor: Beta blockers". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 16 (1): 17–26. doi:10.1016/0278-5846(92)90004-X. PMID 1348368.
- Kaplan HI, Sadock B (1998). Kaplan and Sadock's Synopsis of Psychiatry (8th ed.). Baltimore: Lippincott Williams & Wilkins.
- Robert J. Harmon; et al. (September 1996). "Clonidine for Posttraumatic Stress Disorder in Preschool Children". Journal of the American Academy of Child & Adolescent Psychiatry. 35 (9): 1247–1249. doi:10.1097/00004583-199609000-00022.
- Kinzie, J David; Leung, Paul (September 1989). "Clonidine in Cambodian Patients with Posttraumatic Stress Disorder". Journal of Nervous & Mental Disease. 177 (9): 546–550. doi:10.1097/00005053-198909000-00005. PMID 2769247.
- Horrigan, Joseph P.; Barnhill, L. Jarrett (Aug 1996). "The suppression of nightmares with guanfacine". Journal of Clinical Psychiatry. 57 (8): 371.
- "Prazosin: Biological activity". IUPHAR. International Union of Basic and Clinical Pharmacology. Retrieved 3 June 2016.
- Murray A. Raskind; et al. (February 2003). "Reduction of Nightmares and Other PTSD Symptoms in Combat Veterans by Prazosin: A Placebo-Controlled Study". The American Journal of Psychiatry. 160 (2): 371–373. doi:10.1176/appi.ajp.160.2.371. PMID 12562588.